1 recruiting, 1 terminated. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Recruiting 1, Terminated 1 |
Follow bosutinib: new trials by email Literature Review of bosutinib trials Research Report on bosutinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Asciminib Roll-over Study Asciminib single agent, Imatinib, Nilotinib - Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase 4 | Recruiting | Novartis Pharmaceuticals | 347 | 2022-08-30 | 2026-07-06 |
| Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors Bosutinib - Previously Treated PH + CML | Phase 4 | Terminated | Pfizer | 163 | 2014-11-07 | 2021-12-30 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Blast Crisis (1) · Bronchiolitis Obliterans Syndrome (1) · Leukemia (1) · Myeloproliferative Disorders (1)
Novartis Pharmaceuticals (1) · Pfizer (1)
Austria (2) · France (2) · Germany (2) · Italy (2) · Spain (2) · United States (2) · Argentina (1) · Brazil (1) · Bulgaria (1) · Canada (1) · China (1) · Czechia (1) · Denmark (1) · Japan (1) · Lebanon (1)
PMID 32572189, PMID 35235189, PMID 38007586, PMID 38484432, PMID 39164407
2023 (1)